CAR-T cell therapy research

A Dynamically Regulated Designed IL-2 for Tumor-localized Signaling

This paper designs a dynamically regulated IL-2 variant that enhances tumor-specific immune responses while reducing systemic toxicity.

Genetically inducible coordinators of cytokine signaling pathways for interrogating T cell motility

The paper develops CAMPs, genetically inducible receptors to control cytokine signaling in T cells, to study motility and signaling pathways without paracrine interference.

Structure-function profiling identifies determinants of TCR-T cell therapeutic efficacy

The paper identifies structural and functional determinants of TCR efficacy in adoptive T-cell therapy by comparing two GPC3-specific TCRs using structural and functional assays.

Pan-B-Lineage Targeting with Adapter CAR-T Cells Controls Antigen-Heterogeneous Lymphoma

This study shows that using multiple adapter molecules in AdCAR-T cells can effectively target antigen-heterogeneous lymphoma by overcoming antigen-negative relapse.

Patient-derived ascites reveals functional advantages of γδCAR T-cells within the ovarian cancer-like tumor microenvironment

This study shows that γδCAR T-cells outperform conventional CAR T-cells in an ovarian cancer-like tumor microenvironment despite lower viability.

Deep Learning-based Modeling Enhances Efficacy of Natural Ligand CAR Binders Targeting CD70

This study uses deep learning and physics-based modeling to engineer a CD27 variant that improves the efficacy of CD70-targeting CAR T-cells across multiple cancer models.

BAGEL-CAR: Reflections on the Bits to Binders Competition

The paper reports on a CAR-T therapy binder design competition where their BAGEL-CAR designs achieved high enrichment in experimental screening, highlighting the importance of validating design pipeline outputs.

A Lymphomimetic Synthetic Immune Niche, Consisting of CCL21 and ICAM1, Accelerates the Expansion of Potent CAR T-cells

This paper shows that a synthetic immune niche with CCL21 and ICAM1 boosts CAR T-cell expansion and potency, increasing cell yield and CAR T-cell frequency.

Microbial valerate is associated with CAR T dysbiosis and its supplementation enhances CAR T function in B-cell lymphoma

This study links low stool valerate to CAR T-cell dysfunction in B-cell lymphoma and shows valerate supplementation improves CAR T function.

Rational Control of Basal CAR Expression Improves Discrimination in Inducible T Cell Circuits

This study improves inducible T cell circuits by reducing basal CAR expression, enhancing discrimination between target and off-target cells.

Disruption of the interferon-gamma axis limits chimeric antigen receptor T cell efficacy against acute myeloid leukemia

This study shows that blocking the interferon-gamma axis reduces CAR T cell effectiveness against AML by impairing antigen expression and cytotoxicity, suggesting caution with IFN-gamma inhibitors in AML treatment.

CellCage™ Technology Enables High-throughput Isolation of Defined Cell Combinations to Resolve the Determinants of CAR-T mediated Cytotoxicity

The paper introduces CellCage™ technology to isolate defined cell combinations for high-throughput analysis of CAR-T cell cytotoxicity, revealing functional heterogeneity and cooperative behavior in T cell-mediated killing.

IL-12 restores the sequential cytotoxic capacities of anti-GD2 CAR-T and CAR-iNKT cells against glioblastoma

This study shows that IL-12 enhances the anti-glioblastoma efficacy of GD2-targeted CAR-T and CAR-iNKT cells by improving their persistence and function after repeated antigen exposure.

Cytoskeletal engineering through Formin-like 1 overexpression enhances T cell infiltration and antitumor potency in solid tumors

This study shows that overexpressing FMNL1 in T cells improves their migration through tumor barriers, leading to better antitumor effects in solid tumors.

AI supported in silico screening of chimeric antigen receptor therapy targets

The paper presents a framework integrating AI and computational tools to evaluate CAR target characteristics, using HER2 as a case study to identify liabilities beyond conventional expression analysis.

Deep mapping of structural perturbations to energetics enables precise TCR design

The paper introduces mpTCRai, a deep learning framework that maps structural perturbations to energetic changes in TCRs, enabling precise and safe TCR design for immunotherapy.

Protein design to broadly reprogram engineered T cell function

This paper designs proteins to reprogram T cell signaling pathways, improving CAR-T and TCR-T performance in solid tumor models.

HER2 mutation-derived neoantigens in NSCLC as actionable targets for TCR therapy

The paper identifies TCRs targeting HER2 mutations in NSCLC, showing they recognize mutant epitopes and maintain cytotoxic activity, offering a potential immunotherapy strategy.

Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells

This study develops meditope-enabled CARs to improve T cell functionality and address tumor heterogeneity in CAR therapy.

Tunable Universal OR-gated CAR T cells for AML

This study develops a tunable OR-gated CAR system for AML treatment that effectively targets multiple antigens with reduced engineering complexity and minimized off-target toxicity.

Modular counterplays shape condensation and signaling of chimeric antigen receptor

This study shows that PD-1 disrupts CAR-LCK condensates by binding CAR, and adding a CD3ε module stabilizes these condensates, enhancing CAR T cell activity against solid tumors.

A practical workflow for CAR screening in primary T cells using fitness-guided design and mRNA electroporation

The paper presents a workflow for screening CAR variants in primary T cells using fitness-guided design and mRNA electroporation, identifying improved variants with enhanced cytotoxicity.

Catch-bond engineering surpasses high-affinity maturation for T cell receptor therapies against solid tumors

This study shows that catch-bond engineering improves TCR-T cell therapy efficacy against solid tumors without off-target toxicity, surpassing traditional high-affinity maturation strategies.

Functionalizing hydrogel nanovials with vesicles mimicking antigen-presenting vesicles and cancer exosomes improves T cell capture and activation

Quantifying target antigen-dependent CAR T-cell performance against AML

The paper develops a mathematical model and Bayesian framework to evaluate CAR T-cell efficacy against AML, revealing antigen-specific resistance mechanisms.

BioPathfinder: Evidence-guided multi-agent platform enables hypothesis discovery for CAR-T engineering

A provenance-tracked multi-agent system curated 57 CAR-T patient scRNA-seq studies, generated reviewable hypotheses, and prioritized KLRC1/NKG2A, whose blockade improved CD8+ CAR-T antitumour activity in a Raji xenograft model.

Safety profiling of CAR-T cells using an organotypic human tissue platform

This paper develops an organotypic human tissue platform to assess CAR-T cell toxicity and shows it can predict tissue-specific toxicity profiles and identify factors influencing off-tumor effects.

Engineering antigen-driven co-stimulation and T helper cell activity into TCR-T cells with CD8-41BB fusion receptors enhances anti-tumor activity

This paper enhances TCR-T cell anti-tumor activity by engineering CD8-41BB fusion receptors, improving CD4+ and CD8+ T cell functions and tumor regression in mouse models.

Genome-wide CRISPR Screening Reveals Cullin-1 as a Therapeutic Target Enhancing Efficacy of CD19-directed Immunotherapy

This study identifies Cullin-1 as a target to enhance CD19-directed immunotherapy by preventing CD19 downregulation through inhibition with pevonedistat.

Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion

This study shows that dual stimulation of CD40 and 41BB pathways using a bi-specific molecule enhances CD8+ T cell expansion in TIL cultures.